Startups
The help wanted signs are up across the biopharma industry. Companies are opening and expanding facilities, which is good news for job seekers.
Foresite Labs-incubated company Interline Therapeutics announced Thursday that it had raised $92 million in a financing round co-led by Foresite Capital and ARCH Venture Partners.
Significant contributions were made to the Series A by Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management.
The Series A rounds are the latest in a string of financing announcements made over the past few months.
Catch up on the investment news quickly with BioSpace’s brief overview of the biotech companies hitting the Nasdaq and raking in fresh cash the past week.
Biotechnology firm Ginkgo Bioworks is going public via a merger with Soaring Eagle Acquisition Corp.
Appia is developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients.
Over the past year, the world at large has become more familiar with mRNA technology. Now the world will be introduced to a new type of RNA-based medicine called eRNA.
With 2020 holding a record number of biotech IPOs, this year is lining up to come close. Three more Bay Area life science companies are just about ready to hit the Nasdaq, adding to the growing list for 2021.
Boosted by increased clinical research business in 2020, Science 37 is planning a SPAC merger that will land itself on the Nasdaq and a company value of more than $1 billion and $280 million in gross proceeds.
PRESS RELEASES